TLT — Theralase Technologies Cashflow Statement
0.000.00%
Last trade - 00:00- CA$38.84m
- CA$38.91m
- CA$1.07m
Annual cashflow statement for Theralase Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -7.41 | -5.6 | -4.41 | -5.24 | -4.57 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.422 | 0.93 | 0.342 | 0.241 | 0.648 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.17 | -0.05 | -0.238 | -0.452 | -0.436 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -6.57 | -4.45 | -4.03 | -5.13 | -4.07 |
| Capital Expenditures | -0.533 | -0.165 | -0.101 | -0.07 | -0.037 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.533 | -0.165 | -0.101 | -0.07 | -0.037 |
| Financing Cash Flow Items | -1.6 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 18.6 | -0.058 | -0.057 | 3.02 | 2.65 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | -4.67 | -4.19 | -2.18 | -1.46 |